Journal
CLINICAL & TRANSLATIONAL ONCOLOGY
Volume 19, Issue 3, Pages 273-278Publisher
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s12094-016-1547-4
Keywords
PARP inhibitor; Glioblastoma; Biomarkers; PTEN
Categories
Ask authors/readers for more resources
Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available